{"ticker": {"uuid": "96b2339c-a908-434a-b26b-022fe6bcf64f", "symbol": "EPRX", "name": "Eupraxia Pharmaceuticals Inc.", "exchange": "TOR", "country": "CA", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Why Eupraxia Pharmaceuticals Inc stock is plummeting today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQcjVfdzlYN0RTRVFGSEppTWdfa3liQVkwNkRVQUNHN2NxY3BTYjBQblJuYkRmWGtMWUpPN2VudmxCYXNhWXNZNjZ4MkZYcE1xOFM3X3k5Z3NjVzNSWlQwMDNERW5mWXJPV0JtRlZuR2tmeUhiYjk5UDBiS1pCamxFUUUyM0tRM1h2cFNlUzRvMWRJWVJ3THdwYg?oc=5", "source_name": "Wealth Awesome", "published_at": "2026-07-16T18:27:04+00:00", "published_display": "16 Jul 2026 18:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) reshapes leadership and expands Vancouver-Seattle hubs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQcTA2TGFWWmtvTFlUQmNlLTczQ0RIY3ZNeTN4eUhGS3p0T1U1bUU1bFVjM2hmdVlaYnEwYWRyTm5NbDBaaUZBUTYyTEszNVV3WkdsRmVnSE02MFoteHZJempfc2QtZlRMcVVOdzN2N01PM2Q0ekdQUlBDM0FhSHlqeTdLbkFuZXVxMVp2X3lxTkI2M0pvMnZOblRqbWktVlRMdXdyQVhaSWhhRy1KOEdBVDRVbDhPNW5TWU53cWVfUkNwUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T17:26:29+00:00", "published_display": "15 Jul 2026 17:26", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going On With Eupraxia Pharmaceuticals Inc Stock Tuesday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPU2xGUmdaOVNzREJmY3RrSkM1eWVMVHB5OC11SF8tQzNVcUtwcXJaY0gtRm5mY1F1RXd1cDZNSklHUUVjcW5LUlpfOEV4c3VyLTh0cDFFeEVUM1B0YTRwM0k3SzJJQ0JwQTVqZ2dtdkhKd1RnbHcyajZJekhqc0pGdHJEaEdlY3lsZF9LUFRQTW0xbjNBTm9XazFScXZIdmRvU1Nr?oc=5", "source_name": "Wealth Awesome", "published_at": "2026-07-15T03:32:08+00:00", "published_display": "15 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxPNmFlRWlDQnBhQUpBRHNPMVI5WmdUVVNvck5ydGRYRFg4M0F0V2JYblVtVzhDRzROS0t6X3JiWHlnaUhQbS1NY0ZaS3RYY0oweVVYaURCNElZNFNTcGlTcHdhQmZlMHc3YVFlOURkWEZuNTV0YnptOGNqMVBsaHFYSXJsdndIWFlXbG5sbXp6SWVYSFpXeFVlaU9za3k0NGN5VXh4X2pBaU9lRFROR09jZGNQSlZwbWx2MFdLTEZyOElYSGo3NHp3NHNWMmJaNVl1TlIzXzFtZzZPU3U5bHZEOG9jdDFlWUhpUW15cHluT0hLcE1kdFlhNnlha203WjAxcFl1S1V6WnNmMUJ0VVE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T20:05:00+00:00", "published_display": "13 Jul 2026 20:05", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New drug-development leaders join Eupraxia as it readies Phase 3 push", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNemU4dEk4ZHBXRUFGYy0zYjdhLWJmRGNISFU0Z1ZLaXNOLVFZM1dOWmw0V3NFbklZdWJRU2xJdUtXUXh4eHpKUXdIblpDNFF6cjJRZm1TblNmQ3M4bUVLQjFrYnFOSm9MZ1JQbG1xV3MzTjNHWWJpYkhPRHFHeG5BV2xIM1l4bmp4ang3NkpCUEliOWdhdjQyXzd3M0lmU2VwSEUxQ0U2Z0dYMVEzaURNNUJydFRIV0hlM3hOMQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:05:00+00:00", "published_display": "13 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Eupraxia Pharmaceuticals Inc stock is sliding today", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQN2ZHMUNiWXNqR1NZcVlYSWR4SDBjNlhZUFdYOE55M2dfQ0lyM09WZGNlazB1YzllMWJRSVdxSjJqdXFPOHE1Tjc4TTcxZ3VDQUd6ZXp3QXo5a2RBOF9Cdl93cVE3UnJSWDdoSEtlRkwxcVZvUE11QjRhSGk1MlZNQzRmQUl2WXQ1TFdpbVhhbGxTaXVq?oc=5", "source_name": "Wealth Awesome", "published_at": "2026-07-13T12:22:49+00:00", "published_display": "13 Jul 2026 12:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) Gains 3.8% as Biotech Sector Shows Resilience \u2013 Key Levels to Watch - Long Setup Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQOUZ6eUpUOEZQTkZWVlEzX1VFWmdJZmg3cnNXUWhwYll5MjVlLTNxQlNjUGRnblZuYmdfb1laalZTTUd1cUo4cXJGaU0wbUY5UDl0WG83NmxpVE5uNXExRUtCM2FONUdQd19TN0l4UXl1NFVVcHdDbzNTS1QtTFpoUzJ3d0NpWFZDaUdMdVdOTHp1cVNjOUZ0djktLW84dXc4NVFyWUZkUGhOWWRwTTR6bkxpNzRQdnlkQ0RlVlVWT2paVllJUHV1Tl9FemtQREFm?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) Gains 3.8% as Biotech Sector Shows Resilience \u2013 Key Levels to Watch - Triple MA Cross", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOb3k5WUEtRm1qZkNNZGpwNjVuWUJoa293QzRzT0NBdTNLdkJjZmkzLW1pUEtVMlkzVHBLdTBfejh5SFpaeTlHVFZhSFhiZGdNX3l5SFIzcWJhQlVUb0E2VFNsa08xZDhqLXh3Q1Q1eGE5b3dDRnIxTFFPZkV6UUZESUVJNU9QY2VVZHFqTGFNS291eEg0TVpOU1FBc2otOVNBaVdGSWlYc1hCSlY0YmhXeEc3ZnFYbGVxNjRaOVotVHdDSDBFLTQyMmRGLWg0VVFNTHpn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) adds three drug development and commercialization experts to board", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOek5xa1prdkhmaGJUdXZmc0VSdGFtRzhSR2s3TXdMSF9TRzNUTk9ManNacW5wMXlxMThNZS0xc2dxNzMtM1huZUxUYmN5VUNtY0RueHh4VTRvSkhWQjNCT2dVNWhGVGdnU2lzcDFnTGtzRGxNc3RjU1hvM3ozUnNRVjF2b3NGeng5amx2S0w1dU84QXFfbW92Z0Nha0phcnZadDY0aHZuc2xlc01ENllfdnBlUmwzb1htZkFXVjAzOF9RQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T20:21:07+00:00", "published_display": "07 Jul 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia taps three biotech veterans for board as EP-104GI milestones loom", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNSlpiSlRXRXFkOTVPZFBOb1dqa05fOTk3ckV6RkNLcC1zdmJyeFl6RnpfMnpkN3lfcXM1THNISFJHWlNxa3hpZ0FYYk85cmhzUXhkd3RaQWY2eXlUeDFGSUNJRGRnNENtZjlIakNiTHp1VEdWYXFraXJEc1F0MEd2NWVrVmFRdHh4a2tEUTBKaThQVEFDX3o4ZEVsM29fWEtGakJQdXRPLS1rXzFaZ050RjVlTjlFUFZM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNSzJzNk5qTlFKOEVocWRzSXhfWG91OV9yblcwQmVpd1FxOWtHYVA0YjVHNm5xeXgySTZDNzNveWtsdUJfZUdPLUxzNy1ndE1jZUJCaE9aTGN6aGQ4SkJrS1EzX0s3Q0JlRHFKOVIwWnYwRDFaeHN5dVowRHkwLVNNa3p2TEpKRUo2dk4yVmFaRDNLU2k2ek5ZRUVNZkdOQlVNZVdhMFBYbTVuYzd6U05JX0lKUDRLSUstWGNRa2FNdXU2MHdkSm1nVjI4aWNQYnVwQmwtRjZmaU5zMWZWek1IenJkSjZLTXRKRFlJb3h1TzdUZDR3X1EyRw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9fRFNlLTd6UFlJckRsQ3dBbGs1TmZnS1o2dUtqd3JrNFowVzdITVIxbnFYeWJIekQ0X255azY4NndtWmF4WHE0cExZNEhaeVQzSDVpajNPaEtnY01lRU1LOVB0Z0RfTlQ5ZjR5ckFsRQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T17:42:31+00:00", "published_display": "18 Jun 2026 17:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) confirms mailing of proxy materials to holders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNR0F2cHFKVWlUczVEclpkOWtCRVBreHdUQy1pS2c0TFdtVHg0S05lQTd5TGE3VUs1LXdPcEFqZHhjemZRdWVxMkZTOEJ5MEpUNDJqOXBZM3FiT194ZWJ4dk00MzZQdXIxQWUzV1hvR2htSzlhWW5hcEh2ODlRZXdfVEM5U3Q3S1JrcXFKUWVpR040eUEyU3dCOGFwMlo3dlZBR0NzQmE5WWV4Q2pqYUViRm9vVjhLc0Y3cTYtZnNXaEd0UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Eupraxia heads to New York for Jefferies health conference June 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPbUNSM0Z0VEdvdUNpeVdoTHJmcVowdjE0QzJPUHZwcVpzTHV6eVd2V2hkZlNXY2k3NGkyaExBU1Zaei1vWlplbko2Q2tMeDdLRlFTZDRTVkZxakFsOTRnOXVuNTBlekFwVFM1VTQ0UUFUcnRYTmp1LV9BS1k2dHlKYUY5a1AxQXBFeDZxckJ6NGlZTVNlbHBFMlF2VlJPbjcxU0V6RGtrUU1pTEpXd0x0NWszRjd3blJoLWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNaXRYci15bTk3UUtOUnVVbklMYnYwd2tXdXdiNDdlNkg4M19kbkJrNHNhN1o3a05hU3Nudi00RW5WQ3BMSTdPeFNwQ3lxdEt5VVZMZXY4YkdqMzJDSUFGZHJhNEpta01jXzZwbl9qTGJudGh0WXlGaldLT0YyV0NXZHJ0akRJVW1MQU04bm5EWHVRRVZMZ1Bid1dDMG1TUkR3NGFKN0hNeEtOY3M0aUx6Z25OdjEzTGMxdjZoU0xhd0Z4MmMyQzN3MXJxam5jTV9DT0RiNlZONW8?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Surgeon-scientist Jeymi Tambiah joins Eupraxia as CMO", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQclgtQ3FlRi1YZ19jT3RwdEp4MkR3MnYwS2xVMlFHX1FvT0NEbWJCbGU2TjRQNnZjR1kyN1dXYzNCTDdRLTVNYi1JVmRVaGZ6dWdleTh3YmUwVVdnRGlNU25BR1lHdm8zb0J3ZlM3d3pIX2EtQ2tVWXBCb21pblFpWWQzRnkxYWRxbk1UaWo5S1pGdHBCZDA1QmsxUXQxTEcxbUZ3UjR3UjUtQnViLWFiT1FyQlU0dDFNMkVoS1BlVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Announces Pricing of US$55 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxPNEp6a0o0ZG40NGlndHVfMzZPaVVWb2xaejlxX0lfOXJZMVVFeUI5THhVZDJmVWFZRVdBQzF6VlhQcTJ4Sm1Ra294NUlVSzdqbFU1eWJNXzhQUjVPTmpMN1ByTnh6eXduaWFkYnVLeE9WS2drQVkzZGVBUTdUTnQtQzZ6bFVsOXVCMkREdF9vc1duSHZLNHlMY200UXU4RE1vZ2dmMjJvc29zU21ra3JPN0ZTcFhCVU91dHlmdEtmd0hrTldrNFRoalBhLW02bDBWbmxCM2R0R0Rkc3BjeV94SVd2bEVBbW53SXk0QmJESFBEei1uMkNKUTVoQ2l3QnFzbGVsUERQaVFjd1cxeTNELV82UDJSdzQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Eupraxia plans share sale to fund EoE, Crohn\u2019s trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPdW9qMDgxM3BMZVZ4aUdRb2hva2trUks2T2tlR3prT0F1YzNka1ZHOWFfXzcwcTA3MWhFY0o4XzRMMl9VUVd6YUlta0RxSktVM1RYQThERGZUVUJKd1l5R0wtZ0VjajlETU5ncUs4RkVBWElqLVBJWDB1MHd6Tl9MYWNmLTBWUjNaMTR5UUxqMTAzSjJMelRpY3d3eFhfLVoyWlBVYmpCa1Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE9XZTlzZ094SXR1RGRCMm93a1huenMyQWN3RE1qYi1iT0ZTXzV4djVXeWRpSVY4THJob1BWZ1loOURvVVZFQmMyODluUXZZRF9raXk4RnFUODlTcGdZQ3ZoY01yLTQteVVCM1J3bUtWOUtTZ0w4Q2VSRm1RM0JldGM?oc=5", "source_name": "Market source", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Inc. (TSE:EPRX) surges 15%; retail investors who own 41% shares profited along with institutions", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Inc (EPRX:CT): Stock Price, Quote and News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTFBtMlR2SFI4TE9NTk93c3U5QTFmc05Dc2lmVFFucEdIeFItS1U0NXAwLUk5QlN6cW1HVVlESEY1SVBkQnZVVDM0NV9vUGFWRFNVVTNFZw?oc=5", "source_name": "BNN Bloomberg", "published_at": "2024-07-19T22:24:31+00:00", "published_display": "19 Jul 2024 22:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Why Eupraxia Pharmaceuticals Inc stock is plummeting today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQcjVfdzlYN0RTRVFGSEppTWdfa3liQVkwNkRVQUNHN2NxY3BTYjBQblJuYkRmWGtMWUpPN2VudmxCYXNhWXNZNjZ4MkZYcE1xOFM3X3k5Z3NjVzNSWlQwMDNERW5mWXJPV0JtRlZuR2tmeUhiYjk5UDBiS1pCamxFUUUyM0tRM1h2cFNlUzRvMWRJWVJ3THdwYg?oc=5", "source_name": "Wealth Awesome", "published_at": "2026-07-16T18:27:04+00:00", "published_display": "16 Jul 2026 18:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) reshapes leadership and expands Vancouver-Seattle hubs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQcTA2TGFWWmtvTFlUQmNlLTczQ0RIY3ZNeTN4eUhGS3p0T1U1bUU1bFVjM2hmdVlaYnEwYWRyTm5NbDBaaUZBUTYyTEszNVV3WkdsRmVnSE02MFoteHZJempfc2QtZlRMcVVOdzN2N01PM2Q0ekdQUlBDM0FhSHlqeTdLbkFuZXVxMVp2X3lxTkI2M0pvMnZOblRqbWktVlRMdXdyQVhaSWhhRy1KOEdBVDRVbDhPNW5TWU53cWVfUkNwUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T17:26:29+00:00", "published_display": "15 Jul 2026 17:26", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going On With Eupraxia Pharmaceuticals Inc Stock Tuesday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPU2xGUmdaOVNzREJmY3RrSkM1eWVMVHB5OC11SF8tQzNVcUtwcXJaY0gtRm5mY1F1RXd1cDZNSklHUUVjcW5LUlpfOEV4c3VyLTh0cDFFeEVUM1B0YTRwM0k3SzJJQ0JwQTVqZ2dtdkhKd1RnbHcyajZJekhqc0pGdHJEaEdlY3lsZF9LUFRQTW0xbjNBTm9XazFScXZIdmRvU1Nr?oc=5", "source_name": "Wealth Awesome", "published_at": "2026-07-15T03:32:08+00:00", "published_display": "15 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxPNmFlRWlDQnBhQUpBRHNPMVI5WmdUVVNvck5ydGRYRFg4M0F0V2JYblVtVzhDRzROS0t6X3JiWHlnaUhQbS1NY0ZaS3RYY0oweVVYaURCNElZNFNTcGlTcHdhQmZlMHc3YVFlOURkWEZuNTV0YnptOGNqMVBsaHFYSXJsdndIWFlXbG5sbXp6SWVYSFpXeFVlaU9za3k0NGN5VXh4X2pBaU9lRFROR09jZGNQSlZwbWx2MFdLTEZyOElYSGo3NHp3NHNWMmJaNVl1TlIzXzFtZzZPU3U5bHZEOG9jdDFlWUhpUW15cHluT0hLcE1kdFlhNnlha203WjAxcFl1S1V6WnNmMUJ0VVE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T20:05:00+00:00", "published_display": "13 Jul 2026 20:05", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New drug-development leaders join Eupraxia as it readies Phase 3 push", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNemU4dEk4ZHBXRUFGYy0zYjdhLWJmRGNISFU0Z1ZLaXNOLVFZM1dOWmw0V3NFbklZdWJRU2xJdUtXUXh4eHpKUXdIblpDNFF6cjJRZm1TblNmQ3M4bUVLQjFrYnFOSm9MZ1JQbG1xV3MzTjNHWWJpYkhPRHFHeG5BV2xIM1l4bmp4ang3NkpCUEliOWdhdjQyXzd3M0lmU2VwSEUxQ0U2Z0dYMVEzaURNNUJydFRIV0hlM3hOMQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T20:05:00+00:00", "published_display": "13 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Eupraxia Pharmaceuticals Inc stock is sliding today", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQN2ZHMUNiWXNqR1NZcVlYSWR4SDBjNlhZUFdYOE55M2dfQ0lyM09WZGNlazB1YzllMWJRSVdxSjJqdXFPOHE1Tjc4TTcxZ3VDQUd6ZXp3QXo5a2RBOF9Cdl93cVE3UnJSWDdoSEtlRkwxcVZvUE11QjRhSGk1MlZNQzRmQUl2WXQ1TFdpbVhhbGxTaXVq?oc=5", "source_name": "Wealth Awesome", "published_at": "2026-07-13T12:22:49+00:00", "published_display": "13 Jul 2026 12:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) Gains 3.8% as Biotech Sector Shows Resilience \u2013 Key Levels to Watch - Long Setup Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQOUZ6eUpUOEZQTkZWVlEzX1VFWmdJZmg3cnNXUWhwYll5MjVlLTNxQlNjUGRnblZuYmdfb1laalZTTUd1cUo4cXJGaU0wbUY5UDl0WG83NmxpVE5uNXExRUtCM2FONUdQd19TN0l4UXl1NFVVcHdDbzNTS1QtTFpoUzJ3d0NpWFZDaUdMdVdOTHp1cVNjOUZ0djktLW84dXc4NVFyWUZkUGhOWWRwTTR6bkxpNzRQdnlkQ0RlVlVWT2paVllJUHV1Tl9FemtQREFm?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) Gains 3.8% as Biotech Sector Shows Resilience \u2013 Key Levels to Watch - Triple MA Cross", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOb3k5WUEtRm1qZkNNZGpwNjVuWUJoa293QzRzT0NBdTNLdkJjZmkzLW1pUEtVMlkzVHBLdTBfejh5SFpaeTlHVFZhSFhiZGdNX3l5SFIzcWJhQlVUb0E2VFNsa08xZDhqLXh3Q1Q1eGE5b3dDRnIxTFFPZkV6UUZESUVJNU9QY2VVZHFqTGFNS291eEg0TVpOU1FBc2otOVNBaVdGSWlYc1hCSlY0YmhXeEc3ZnFYbGVxNjRaOVotVHdDSDBFLTQyMmRGLWg0VVFNTHpn?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) adds three drug development and commercialization experts to board", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOek5xa1prdkhmaGJUdXZmc0VSdGFtRzhSR2s3TXdMSF9TRzNUTk9ManNacW5wMXlxMThNZS0xc2dxNzMtM1huZUxUYmN5VUNtY0RueHh4VTRvSkhWQjNCT2dVNWhGVGdnU2lzcDFnTGtzRGxNc3RjU1hvM3ozUnNRVjF2b3NGeng5amx2S0w1dU84QXFfbW92Z0Nha0phcnZadDY0aHZuc2xlc01ENllfdnBlUmwzb1htZkFXVjAzOF9RQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T20:21:07+00:00", "published_display": "07 Jul 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia taps three biotech veterans for board as EP-104GI milestones loom", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNSlpiSlRXRXFkOTVPZFBOb1dqa05fOTk3ckV6RkNLcC1zdmJyeFl6RnpfMnpkN3lfcXM1THNISFJHWlNxa3hpZ0FYYk85cmhzUXhkd3RaQWY2eXlUeDFGSUNJRGRnNENtZjlIakNiTHp1VEdWYXFraXJEc1F0MEd2NWVrVmFRdHh4a2tEUTBKaThQVEFDX3o4ZEVsM29fWEtGakJQdXRPLS1rXzFaZ050RjVlTjlFUFZM?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxNSzJzNk5qTlFKOEVocWRzSXhfWG91OV9yblcwQmVpd1FxOWtHYVA0YjVHNm5xeXgySTZDNzNveWtsdUJfZUdPLUxzNy1ndE1jZUJCaE9aTGN6aGQ4SkJrS1EzX0s3Q0JlRHFKOVIwWnYwRDFaeHN5dVowRHkwLVNNa3p2TEpKRUo2dk4yVmFaRDNLU2k2ek5ZRUVNZkdOQlVNZVdhMFBYbTVuYzd6U05JX0lKUDRLSUstWGNRa2FNdXU2MHdkSm1nVjI4aWNQYnVwQmwtRjZmaU5zMWZWek1IenJkSjZLTXRKRFlJb3h1TzdUZDR3X1EyRw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTE9fRFNlLTd6UFlJckRsQ3dBbGs1TmZnS1o2dUtqd3JrNFowVzdITVIxbnFYeWJIekQ0X255azY4NndtWmF4WHE0cExZNEhaeVQzSDVpajNPaEtnY01lRU1LOVB0Z0RfTlQ5ZjR5ckFsRQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T17:42:31+00:00", "published_display": "18 Jun 2026 17:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals (EPRX) confirms mailing of proxy materials to holders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNR0F2cHFKVWlUczVEclpkOWtCRVBreHdUQy1pS2c0TFdtVHg0S05lQTd5TGE3VUs1LXdPcEFqZHhjemZRdWVxMkZTOEJ5MEpUNDJqOXBZM3FiT194ZWJ4dk00MzZQdXIxQWUzV1hvR2htSzlhWW5hcEh2ODlRZXdfVEM5U3Q3S1JrcXFKUWVpR040eUEyU3dCOGFwMlo3dlZBR0NzQmE5WWV4Q2pqYUViRm9vVjhLc0Y3cTYtZnNXaEd0UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Eupraxia heads to New York for Jefferies health conference June 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPbUNSM0Z0VEdvdUNpeVdoTHJmcVowdjE0QzJPUHZwcVpzTHV6eVd2V2hkZlNXY2k3NGkyaExBU1Zaei1vWlplbko2Q2tMeDdLRlFTZDRTVkZxakFsOTRnOXVuNTBlekFwVFM1VTQ0UUFUcnRYTmp1LV9BS1k2dHlKYUY5a1AxQXBFeDZxckJ6NGlZTVNlbHBFMlF2VlJPbjcxU0V6RGtrUU1pTEpXd0x0NWszRjd3blJoLWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNaXRYci15bTk3UUtOUnVVbklMYnYwd2tXdXdiNDdlNkg4M19kbkJrNHNhN1o3a05hU3Nudi00RW5WQ3BMSTdPeFNwQ3lxdEt5VVZMZXY4YkdqMzJDSUFGZHJhNEpta01jXzZwbl9qTGJudGh0WXlGaldLT0YyV0NXZHJ0akRJVW1MQU04bm5EWHVRRVZMZ1Bid1dDMG1TUkR3NGFKN0hNeEtOY3M0aUx6Z25OdjEzTGMxdjZoU0xhd0Z4MmMyQzN3MXJxam5jTV9DT0RiNlZONW8?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Surgeon-scientist Jeymi Tambiah joins Eupraxia as CMO", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQclgtQ3FlRi1YZ19jT3RwdEp4MkR3MnYwS2xVMlFHX1FvT0NEbWJCbGU2TjRQNnZjR1kyN1dXYzNCTDdRLTVNYi1JVmRVaGZ6dWdleTh3YmUwVVdnRGlNU25BR1lHdm8zb0J3ZlM3d3pIX2EtQ2tVWXBCb21pblFpWWQzRnkxYWRxbk1UaWo5S1pGdHBCZDA1QmsxUXQxTEcxbUZ3UjR3UjUtQnViLWFiT1FyQlU0dDFNMkVoS1BlVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Announces Pricing of US$55 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxPNEp6a0o0ZG40NGlndHVfMzZPaVVWb2xaejlxX0lfOXJZMVVFeUI5THhVZDJmVWFZRVdBQzF6VlhQcTJ4Sm1Ra294NUlVSzdqbFU1eWJNXzhQUjVPTmpMN1ByTnh6eXduaWFkYnVLeE9WS2drQVkzZGVBUTdUTnQtQzZ6bFVsOXVCMkREdF9vc1duSHZLNHlMY200UXU4RE1vZ2dmMjJvc29zU21ra3JPN0ZTcFhCVU91dHlmdEtmd0hrTldrNFRoalBhLW02bDBWbmxCM2R0R0Rkc3BjeV94SVd2bEVBbW53SXk0QmJESFBEei1uMkNKUTVoQ2l3QnFzbGVsUERQaVFjd1cxeTNELV82UDJSdzQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Eupraxia plans share sale to fund EoE, Crohn\u2019s trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPdW9qMDgxM3BMZVZ4aUdRb2hva2trUks2T2tlR3prT0F1YzNka1ZHOWFfXzcwcTA3MWhFY0o4XzRMMl9VUVd6YUlta0RxSktVM1RYQThERGZUVUJKd1l5R0wtZ0VjajlETU5ncUs4RkVBWElqLVBJWDB1MHd6Tl9MYWNmLTBWUjNaMTR5UUxqMTAzSjJMelRpY3d3eFhfLVoyWlBVYmpCa1Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE9XZTlzZ094SXR1RGRCMm93a1huenMyQWN3RE1qYi1iT0ZTXzV4djVXeWRpSVY4THJob1BWZ1loOURvVVZFQmMyODluUXZZRF9raXk4RnFUODlTcGdZQ3ZoY01yLTQteVVCM1J3bUtWOUtTZ0w4Q2VSRm1RM0JldGM?oc=5", "source_name": "Market source", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Inc. (TSE:EPRX) surges 15%; retail investors who own 41% shares profited along with institutions", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eupraxia Pharmaceuticals Inc (EPRX:CT): Stock Price, Quote and News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTFBtMlR2SFI4TE9NTk93c3U5QTFmc05Dc2lmVFFucEdIeFItS1U0NXAwLUk5QlN6cW1HVVlESEY1SVBkQnZVVDM0NV9vUGFWRFNVVTNFZw?oc=5", "source_name": "BNN Bloomberg", "published_at": "2024-07-19T22:24:31+00:00", "published_display": "19 Jul 2024 22:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 76, "total_relevant": 21, "sentiment_summary": {"positive": 6, "negative": 0, "neutral": 15, "score": 55, "total": 21, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 89, "events": [{"event": "general", "label": "Market update", "weight": 9.7, "count": 17}, {"event": "earnings", "label": "Earnings", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 6, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 9.46, "latest_week": "2026-07-10", "one_week_move": -0.7, "four_week_move": 12.0, "twelve_week_move": -2.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.226085, "market_dynamics_buy_signal": false, "relative_strength": -7.592213, "fair_value_gap": 45.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.5285, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.7% over one week, +12.0% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 8}, {"label": "Wealth Awesome", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "dars.gov.et", "count": 2}, {"label": "The Globe and Mail", "count": 1}, {"label": "TradingKey", "count": 1}, {"label": "Market source", "count": 1}, {"label": "simplywall.st", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 21}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 17}, {"label": "Earnings", "count": 3}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "89/100 classification confidence."}, {"label": "Company focus", "value": "21", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.7% over one week, +12.0% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Why Eupraxia Pharmaceuticals Inc stock is plummeting today"}], "updated_at": "2026-07-17T16:46:17.817948+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}